University of Sussex
Browse
IRF4 in multiple myeloma - accepted version.pdf (922.26 kB)

IRF4 in multiple myeloma—biology, disease and therapeutic target

Download (922.26 kB)
journal contribution
posted on 2023-06-09, 14:30 authored by Alessandro Agnarelli, Timothy ChevassutTimothy Chevassut, Erika ManciniErika Mancini
Multiple Myeloma (MM) is an incurable hematologic malignancy characterized by abnormal proliferation of plasma cells. Interferon Regulatory Factor 4 (IRF4), a member of the interferon regulatory family of transcription factors, is central to the genesis of MM. IRF4 is highly expressed in B cells and plasma cells where it plays essential roles in controlling B cell to plasma cell differentiation and immunoglobulin class switching. Overexpression of IRF4 is found in MM patients’ derived cells, often as a result of activating mutations or translocations, where it is required for their survival. In this review, we rst describe the roles fi of IRF4 in B cells and plasma cells and then analyse the subversion of the IRF4 transcriptional network in MM. Moreover, we discuss current therapies for MM as well as direct targeting of IRF4 as a potential new therapeutic strategy.

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Leukemia Research

ISSN

0145-2126

Publisher

Elsevier

Volume

72

Page range

52-58

Department affiliated with

  • Clinical and Experimental Medicine Publications

Research groups affiliated with

  • Haematology Research Group Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2018-08-10

First Open Access (FOA) Date

2019-08-03

First Compliant Deposit (FCD) Date

2018-08-10

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC